

K Dane Wittrup

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9579895/publications.pdf>

Version: 2024-02-01

191
papers

16,701
citations

14655

66
h-index

17592

121
g-index

195
all docs

195
docs citations

195
times ranked

15982
citing authors

#	ARTICLE	IF	CITATIONS
1	Yeast surface display for screening combinatorial polypeptide libraries. <i>Nature Biotechnology</i> , 1997, 15, 553-557.	17.5	1,579
2	Isolating and engineering human antibodies using yeast surface display. <i>Nature Protocols</i> , 2006, 1, 755-768.	12.0	792
3	A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2861-2871.	4.1	497
4	Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 1421-1434.	13.7	471
5	Flow-cytometric isolation of human antibodies from a nonimmune <i>Saccharomyces cerevisiae</i> surface display library. <i>Nature Biotechnology</i> , 2003, 21, 163-170.	17.5	462
6	Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. <i>Nature Medicine</i> , 2016, 22, 1402-1410.	30.7	437
7	Biophysical properties of the clinical-stage antibody landscape. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 944-949.	7.1	433
8	Monovalent, reduced-size quantum dots for imaging receptors on living cells. <i>Nature Methods</i> , 2008, 5, 397-399.	19.0	398
9	Yeast surface display for protein engineering and characterization. <i>Current Opinion in Structural Biology</i> , 2007, 17, 467-473.	5.7	366
10	Computational design of antibody-affinity improvement beyond in vivo maturation. <i>Nature Biotechnology</i> , 2007, 25, 1171-1176.	17.5	310
11	Enhanced CAR ^T cell activity against solid tumors by vaccine boosting through the chimeric receptor. <i>Science</i> , 2019, 365, 162-168.	12.6	282
12	[25] Yeast surface display for directed evolution of protein expression, affinity, and stability. <i>Methods in Enzymology</i> , 2000, 328, 430-444.	1.0	280
13	Increasing the secretory capacity of <i>Saccharomyces cerevisiae</i> for production of single-chain antibody fragments. <i>Nature Biotechnology</i> , 1998, 16, 773-777.	17.5	244
14	Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. <i>Journal of Clinical Investigation</i> , 2017, 127, 2176-2191.	8.2	241
15	Design Criteria for Engineering Inorganic Material-Specific Peptides. <i>Langmuir</i> , 2005, 21, 6929-6933.	3.5	198
16	Protein engineering by cell-surface display. <i>Current Opinion in Biotechnology</i> , 2001, 12, 395-399.	6.6	186
17	Protein Disulfide Isomerase Overexpression Increases Secretion of Foreign Proteins in <i>Saccharomyces cerevisiae</i> . <i>Bio/technology</i> , 1994, 12, 381-384.	1.5	185
18	Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in <i>Saccharomyces cerevisiae</i> . <i>Biotechnology and Bioengineering</i> , 2009, 103, 1192-1201.	3.3	181

#	ARTICLE	IF	CITATIONS
19	Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity. <i>Cancer Research</i> , 2013, 73, 1547-1558.	0.9	176
20	Factors determining antibody distribution in tumors. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 57-61.	8.7	174
21	Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17616-17621.	7.1	173
22	Manipulating the Selection Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies. <i>Cell</i> , 2015, 160, 785-797.	28.9	173
23	Aglycosylated immunoglobulin G₁ variants productively engage activating Fc receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20167-20172.	7.1	169
24	Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2. <i>Cancer Cell</i> , 2015, 27, 489-501.	16.8	158
25	Picomolar Affinity Fibronectin Domains Engineered Utilizing Loop Length Diversity, Recursive Mutagenesis, and Loop Shuffling. <i>Journal of Molecular Biology</i> , 2008, 381, 1238-1252.	4.2	148
26	Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 663-670.	2.1	147
27	Practical Theoretic Guidance for the Design of Tumor-Targeting Agents. <i>Methods in Enzymology</i> , 2012, 503, 255-268.	1.0	143
28	Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	141
29	Fine Affinity Discrimination by Yeast Surface Display and Flow Cytometry. <i>Biotechnology Progress</i> , 2000, 16, 31-37.	2.6	140
30	Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. <i>Cancer Research</i> , 2003, 63, 1288-96.	0.9	140
31	Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses. <i>Journal of Immunology</i> , 2009, 182, 1541-1547.	0.8	136
32	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13252-13257.	7.1	135
33	Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C. <i>Protein Engineering, Design and Selection</i> , 2004, 17, 293-304.	2.1	130
34	Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface Display. <i>Journal of Molecular Biology</i> , 2004, 342, 539-550.	4.2	129
35	Optimal Screening of Surface-Displayed Polypeptide Libraries. <i>Biotechnology Progress</i> , 1998, 14, 55-62.	2.6	127
36	Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. <i>Immunity</i> , 2022, 55, 308-323.e9.	14.3	126

#	ARTICLE	IF	CITATIONS
37	Five birds, one stone: Neutralization of α -hemolysin and 4 bi-component leukocidins of <i>Staphylococcus aureus</i> with a single human monoclonal antibody. <i>MAbs</i> , 2015, 7, 243-254.	5.2	125
38	Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor. <i>Journal of Biological Chemistry</i> , 2004, 279, 30375-30384.	3.4	122
39	Engineering Antibody Affinity by Yeast Surface Display. <i>Methods in Enzymology</i> , 2004, 388, 348-358.	1.0	121
40	Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. <i>Nature Cancer</i> , 2020, 1, 882-893.	13.2	113
41	Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control. <i>Journal of Biological Chemistry</i> , 1998, 273, 19453-19458.	3.4	110
42	Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases. <i>Journal of Nuclear Medicine</i> , 2007, 48, 995-999.	5.0	108
43	Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids. <i>Cancer Research</i> , 2008, 68, 3334-3341.	0.9	106
44	High-affinity lamprey VLRA and VLRB monoclonal antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12891-12896.	7.1	104
45	A modular IgG-scFv bispecific antibody topology. <i>Protein Engineering, Design and Selection</i> , 2010, 23, 221-228.	2.1	104
46	An Integrating Vector for Tunable, High Copy, Stable Integration into the Dispersed Ty ⁺ Sites of <i>Saccharomyces cerevisiae</i> . <i>Biotechnology Progress</i> , 1996, 12, 16-21.	2.6	102
47	Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3320-3325.	7.1	97
48	Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2233-2240.	4.1	96
49	Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies. <i>Journal of Molecular Biology</i> , 2007, 368, 1024-1041.	4.2	95
50	Selection of Horseradish Peroxidase Variants with Enhanced Enantioselectivity by Yeast Surface Display. <i>Chemistry and Biology</i> , 2007, 14, 1176-1185.	6.0	94
51	Development of a Human Light Chain Variable Domain (VL) Intracellular Antibody Specific for the Amino Terminus of Huntingtin via Yeast Surface Display. <i>Journal of Molecular Biology</i> , 2004, 342, 901-912.	4.2	93
52	Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface. <i>Structure</i> , 2013, 21, 1966-1978.	3.3	93
53	Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. <i>Journal of Immunological Methods</i> , 2004, 287, 147-158.	1.4	90
54	Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. <i>Nucleic Acids Research</i> , 2004, 32, 36e-36.	14.5	89

#	ARTICLE	IF	CITATIONS
55	Bispecific Designed Ankyrin Repeat Proteins (DARPs) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling. <i>Journal of Biological Chemistry</i> , 2011, 286, 41273-41285.	3.4	89
56	Immunotherapy: The Path to Win the War on Cancer?. <i>Cell</i> , 2015, 161, 185-186.	28.9	86
57	A mechanistic compartmental model for total antibody uptake in tumors. <i>Journal of Theoretical Biology</i> , 2012, 314, 57-68.	1.7	85
58	Protein Engineering and Selection Using Yeast Surface Display. <i>Methods in Molecular Biology</i> , 2015, 1319, 3-36.	0.9	83
59	Reduction of BiP Levels Decreases Heterologous Protein Secretion in <i>Saccharomyces cerevisiae</i> . <i>Journal of Biological Chemistry</i> , 1996, 271, 10017-10022.	3.4	82
60	Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1879-1890.	4.2	80
61	A small-molecule catalyst of protein folding in vitro and in vivo. <i>Chemistry and Biology</i> , 1999, 6, 871-879.	6.0	79
62	Secretion Efficiency in <i>Saccharomyces cerevisiae</i> of Bovine Pancreatic Trypsin Inhibitor Mutants Lacking Disulfide Bonds Is Correlated with Thermodynamic Stability. <i>Biochemistry</i> , 1998, 37, 1264-1273.	2.5	78
63	Highly avid magnetic bead capture: An efficient selection method for de novo protein engineering utilizing yeast surface display. <i>Biotechnology Progress</i> , 2009, 25, 774-783.	2.6	77
64	Stability and CDR Composition Biases Enrich Binder Functionality Landscapes. <i>Journal of Molecular Biology</i> , 2010, 401, 84-96.	4.2	76
65	High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. <i>MAbs</i> , 2015, 7, 770-777.	5.2	76
66	Quantitative Screening of Yeast Surface-Displayed Polypeptide Libraries by Magnetic Bead Capture. <i>Biotechnology Progress</i> , 2002, 18, 212-220.	2.6	73
67	Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5082-5087.	7.1	69
68	Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties. <i>Journal of Biological Chemistry</i> , 2011, 286, 4165-4172.	3.4	66
69	Stochastic kinetics of intracellular huntingtin aggregate formation. <i>Nature Chemical Biology</i> , 2006, 2, 319-323.	8.0	65
70	Rapid tolerization of virus-activated tumor-specific CD8 ⁺ T cells in prostate tumors of TRAMP mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13003-13008.	7.1	65
71	Yeast Surface Display for Antibody Isolation: Library Construction, Library Screening, and Affinity Maturation. <i>Methods in Molecular Biology</i> , 2014, 1131, 151-181.	0.9	65
72	Degradation of Mutated Bovine Pancreatic Trypsin Inhibitor in the Yeast Vacuole Suggests Post-endoplasmic Reticulum Protein Quality Control. <i>Journal of Biological Chemistry</i> , 2004, 279, 15289-15297.	3.4	64

#	ARTICLE	IF	CITATIONS
73	High-Affinity CD25-Binding IL-2 Mutants Potently Stimulate Persistent T Cell Growth. <i>Biochemistry</i> , 2005, 44, 10696-10701.	2.5	63
74	Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 62, 1026-1035.	2.6	62
75	High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming. <i>Nature Communications</i> , 2021, 12, 773.	12.8	62
76	A33 antigen displays persistent surface expression. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1017-1027.	4.2	61
77	Probing the interface between biomolecules and inorganic materials using yeast surface display and genetic engineering. <i>Acta Biomaterialia</i> , 2005, 1, 145-154.	8.3	60
78	Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. <i>AAPS Journal</i> , 2016, 18, 635-646.	4.4	60
79	Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire. <i>Biotechnology and Bioengineering</i> , 2007, 97, 1009-1020.	3.3	59
80	Interleukin-2 mutants with enhanced $\tilde{\text{A}}$ -receptor subunit binding affinity. <i>Protein Engineering, Design and Selection</i> , 2003, 16, 1081-1087.	2.1	58
81	Lack of CD8 ⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. <i>Science Immunology</i> , 2021, 6, eabi8800.	11.9	58
82	Improved mutants from directed evolution are biased to orthologous substitutions. <i>Protein Engineering, Design and Selection</i> , 2006, 19, 245-253.	2.1	57
83	Rapid Conformational Epitope Mapping of Anti-gp120 Antibodies with a Designed Mutant Panel Displayed on Yeast. <i>Journal of Molecular Biology</i> , 2013, 425, 444-456.	4.2	56
84	Intratumorally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. <i>Nature Biomedical Engineering</i> , 2022, 6, 129-143.	22.5	56
85	Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. <i>Nuclear Medicine and Biology</i> , 2011, 38, 223-233.	0.6	55
86	An engineered protein antagonist of K-Ras/B-Raf interaction. <i>Scientific Reports</i> , 2017, 7, 5831.	3.3	55
87	Rapid Method for Measuring ScFv Thermal Stability by Yeast Surface Display. <i>Biotechnology Progress</i> , 2003, 19, 631-638.	2.6	54
88	Structural Model of the mAb 806-EGFR Complex Using Computational Docking followed by Computational and Experimental Mutagenesis. <i>Structure</i> , 2006, 14, 401-414.	3.3	52
89	A switchable yeast display/secretion system. <i>Protein Engineering, Design and Selection</i> , 2015, 28, 317-325.	2.1	52
90	Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. <i>Integrative Biology (United Kingdom)</i> , 2014, 6, 388-398.	1.3	51

#	ARTICLE	IF	CITATIONS
91	A single-cell assay of β -galactosidase activity in <i>Saccharomyces cerevisiae</i> . <i>Cytometry</i> , 1988, 9, 394-404.	1.8	50
92	What, Why, Where, and When: Bringing Timing to Immuno-Oncology. <i>Trends in Immunology</i> , 2019, 40, 12-21.	6.8	50
93	Expression of the 180-kD Ribosome Receptor Induces Membrane Proliferation and Increased Secretory Activity in Yeast. <i>Journal of Cell Biology</i> , 1999, 146, 273-284.	5.2	49
94	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. <i>Blood</i> , 2018, 131, 611-620.	1.4	49
95	Highly <i>l</i> - and <i>d</i> -enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17694-17699.	7.1	48
96	Engineering Fibronectin-Based Binding Proteins by Yeast Surface Display. <i>Methods in Enzymology</i> , 2013, 523, 303-326.	1.0	47
97	Expression Level Tuning for Optimal Heterologous Protein Secretion in <i>Saccharomyces cerevisiae</i> . <i>Biotechnology Progress</i> , 1997, 13, 117-122.	2.6	46
98	Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency. <i>Journal of Immunology</i> , 2008, 180, 1576-1583.	0.8	46
99	Emergent Properties of Nanosensor Arrays: Applications for Monitoring IgG Affinity Distributions, Weakly Affined Hypermannosylation, and Colony Selection for Biomanufacturing. <i>ACS Nano</i> , 2013, 7, 7472-7482.	14.6	45
100	Maximizing response to intratumoral immunotherapy in mice by tuning local retention. <i>Nature Communications</i> , 2022, 13, 109.	12.8	45
101	Constitutive overexpression of secreted heterologous proteins decreases extractable heavy chain binding protein and protein disulfide isomerase levels in <i>Saccharomyces cerevisiae</i> . <i>Biotechnology Progress</i> , 1995, 11, 171-177.	2.6	44
102	Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. <i>Nature Biotechnology</i> , 2005, 23, 191-194.	17.5	44
103	Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries. <i>Journal of Molecular Biology</i> , 2018, 430, 119-130.	4.2	44
104	Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. <i>Nature Biomedical Engineering</i> , 2020, 4, 636-648.	22.5	44
105	Molecular Magnetic Resonance Imaging of Tumor Response to Therapy. <i>Scientific Reports</i> , 2015, 5, 14759.	3.3	43
106	Interleukin 2 (IL-2) Variants Engineered for Increased IL-2 Receptor α -Subunit Affinity Exhibit Increased Potency Arising from a Cell Surface Ligand Reservoir Effect. <i>Molecular Pharmacology</i> , 2004, 66, 864-869.	2.3	42
107	Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library. <i>Journal of Biological Chemistry</i> , 2016, 291, 22496-22508.	3.4	42
108	Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. <i>Journal of Experimental Medicine</i> , 2017, 214, 1679-1690.	8.5	41

#	ARTICLE	IF	CITATIONS
109	Disulfide bond formation and eukaryotic secretory productivity. <i>Current Opinion in Biotechnology</i> , 1995, 6, 203-208.	6.6	38
110	Contrasting secretory processing of simultaneously expressed heterologous proteins in <i>Saccharomyces cerevisiae</i> . <i>Biotechnology and Bioengineering</i> , 2006, 93, 896-905.	3.3	38
111	Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells. <i>Journal of Immunotherapy</i> , 2009, 32, 887-894.	2.4	38
112	Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶ Y- or ¹⁷⁷ Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 925-937.	6.4	38
113	Effect of Small-Molecule Binding Affinity on Tumor Uptake <i>In Vivo</i> : A Systematic Study Using a Pretargeted Bispecific Antibody. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1365-1372.	4.1	37
114	Temporally Programmed CD8 ⁺ + DC Activation Enhances Combination Cancer Immunotherapy. <i>Cell Reports</i> , 2016, 17, 2503-2511.	6.4	37
115	Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). <i>AAPS Journal</i> , 2016, 18, 861-875.	4.4	37
116	A graphene-based physiometer array for the analysis of single biological cells. <i>Scientific Reports</i> , 2014, 4, 6865.	3.3	36
117	Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1735-1742.	5.0	36
118	Dose Dependence of Intratumoral Perivascular Distribution of Monoclonal Antibodies. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 860-867.	3.3	35
119	Biosynthetic polypeptide libraries. <i>Current Opinion in Biotechnology</i> , 1999, 10, 117-122.	6.6	34
120	Target-independent variable region mediated effects on antibody clearance can be FcRn independent. <i>MAbs</i> , 2016, 8, 1269-1275.	5.2	34
121	Directed evolution for improved secretion of cancer testis antigen NY-ESO-1 from yeast. <i>Protein Expression and Purification</i> , 2006, 48, 232-242.	1.3	33
122	The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. <i>Protein Engineering, Design and Selection</i> , 2010, 23, 211-219.	2.1	33
123	A Disulfide-Free Single-Domain VL Intrabody with Blocking Activity towards Huntingtin Reveals a Novel Mode of Epitope Recognition. <i>Journal of Molecular Biology</i> , 2011, 414, 337-355.	4.2	33
124	Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells. <i>Journal of Immunology</i> , 2012, 189, 1708-1716.	0.8	32
125	A Flow Cytometric Assay for Screening Improved Heterologous Protein Secretion in Yeast. <i>Biotechnology Progress</i> , 2006, 22, 1200-1208.	2.6	31
126	Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression. <i>Journal of Molecular Biology</i> , 2012, 422, 532-544.	4.2	30

#	ARTICLE	IF	CITATIONS
127	A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 187-193.	2.1	30
128	Antitumor Antibodies Can Drive Therapeutic T Cell Responses. <i>Trends in Cancer</i> , 2017, 3, 615-620.	7.4	29
129	Phage on display. <i>Trends in Biotechnology</i> , 1999, 17, 423-424.	9.3	28
130	Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment. <i>Protein Science</i> , 2006, 15, 324-334.	7.6	28
131	Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1774-1782.	4.1	27
132	Chaperone proteins as single component reagents to assess antibody nonspecificity. <i>MAbs</i> , 2017, 9, 1036-1040.	5.2	26
133	Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. <i>Protein Engineering, Design and Selection</i> , 2012, 25, 47-57.	2.1	25
134	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. <i>Cancer Research</i> , 2016, 76, 6669-6679.	0.9	25
135	Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. <i>Nature Communications</i> , 2018, 9, 1461.	12.8	25
136	Detection of amyloid β oligomers toward early diagnosis of Alzheimer's disease. <i>Analytical Biochemistry</i> , 2019, 566, 40-45.	2.4	25
137	Integrated Mimicry of B Cell Antibody Mutagenesis Using Yeast Homologous Recombination. <i>Molecular Biotechnology</i> , 2011, 47, 57-69.	2.4	24
138	Nonspecificity in a nonimmune human scFv repertoire. <i>MAbs</i> , 2017, 9, 1029-1035.	5.2	24
139	Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy. <i>Molecular Imaging and Biology</i> , 2011, 13, 215-221.	2.6	22
140	Tumor cells are dislodged into the pulmonary vein during lobectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 3224-3231.e5.	0.8	22
141	Generation of Fluorogen-Activating Designed Ankyrin Repeat Proteins (FADAs) as Versatile Sensor Tools. <i>Journal of Molecular Biology</i> , 2016, 428, 1272-1289.	4.2	22
142	Propagation of an amplifiable recombinant plasmid in <i>Saccharomyces cerevisiae</i> : flow cytometry studies and segregated modeling. <i>Biotechnology and Bioengineering</i> , 1990, 35, 565-577.	3.3	21
143	Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. <i>MAbs</i> , 2017, 9, 257-268.	5.2	19
144	Cutting Edge: Delay and Reversal of T Cell Tolerance by Intratumoral Injection of Antigen-Loaded Dendritic Cells in an Autochthonous Tumor Model. <i>Journal of Immunology</i> , 2010, 184, 5954-5958.	0.8	18

#	ARTICLE	IF	CITATIONS
145	Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles. <i>Biomacromolecules</i> , 2013, 14, 1093-1102.	5.4	18
146	Leader peptide efficiency correlates with signal recognition particle dependence in <i>Saccharomyces cerevisiae</i> . , 1998, 59, 286-293.		17
147	Single-chain antibody fragment-based adsorbent for the extracorporeal removal of β_2 -microglobulin. <i>Kidney International</i> , 2004, 65, 310-322.	5.2	15
148	Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles. <i>Journal of Immunotherapy</i> , 2008, 31, 607-619.	2.4	15
149	Activation of Tolerogenic Dendritic Cells in the Tumor Draining Lymph Nodes by CD8+T Cells Engineered to Express CD40 Ligand. <i>Journal of Immunology</i> , 2010, 184, 3394-3400.	0.8	15
150	Thermodynamic characterization of affinity maturation: the D1.3 antibody and a higher-affinity mutant. , 1998, 11, 10-13.		14
151	Glutathione excretion in response to heterologous protein secretion in <i>saccharomyces cerevisiae</i> . , 2000, 68, 389-395.		14
152	Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. <i>International Journal of Cancer</i> , 2013, 133, 2925-2933.	5.1	14
153	Rolling Adhesion Kinematics of Yeast Engineered To Express Selectins. <i>Biotechnology Progress</i> , 2003, 19, 1033-1037.	2.6	13
154	A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 4409-4416.	3.3	13
155	Antibody-Mediated Neutralization of Perfringolysin O for Intracellular Protein Delivery. <i>Molecular Pharmaceutics</i> , 2015, 12, 1992-2000.	4.6	13
156	Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIAs. <i>Journal of Molecular Biology</i> , 2017, 429, 2528-2541.	4.2	13
157	Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 330.	2.8	12
158	Design Principles for SuCESsFul Biosensors: Specific Fluorophore/Analyte Binding and Minimization of Fluorophore/Scaffold Interactions. <i>Journal of Molecular Biology</i> , 2016, 428, 4228-4241.	4.2	11
159	Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. <i>Nucleic Acids Research</i> , 2017, 45, 7602-7614.	14.5	11
160	Intratumorally anchored cytokine therapy. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 725-732.	5.0	11
161	Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine Fc γ R Types. <i>Journal of Molecular Biology</i> , 2018, 430, 1786-1798.	4.2	10
162	Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models. <i>Oncolmmunology</i> , 2019, 8, e1558678.	4.6	10

#	ARTICLE	IF	CITATIONS
163	Mathematical modeling of a single-cell enzyme assay. <i>Biotechnology and Bioengineering</i> , 1990, 35, 525-532.	3.3	9
164	Yeast Display and Selections. , 2010, , 207-233.		9
165	A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e162.	5.1	9
166	A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1773-1780.	4.1	8
167	A high affinity human antibody antagonist of P-selectin mediated rolling. <i>Biochemical and Biophysical Research Communications</i> , 2006, 350, 508-513.	2.1	7
168	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2575-2584.	4.1	7
169	The single cell as a microplate well. <i>Nature Biotechnology</i> , 2000, 18, 1039-1040.	17.5	6
170	Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico. <i>MAbs</i> , 2019, 11, 803-808.	5.2	6
171	Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice. <i>PLoS ONE</i> , 2021, 16, e0248903.	2.5	6
172	A mathematical model of recombinational amplification of the 2 ^{1/4} plasmid in the yeast <i>Saccharomyces cerevisiae</i> . <i>Journal of Theoretical Biology</i> , 1988, 130, 481-492.	1.7	5
173	Role of the Protein-Folding Chaperone BiP in Secretion of Foreign Proteins in Eukaryotic Cells. <i>ACS Symposium Series</i> , 1993, , 121-132.	0.5	5
174	Equilibrium and dynamic design principles for binding molecules engineered for reagentless biosensors. <i>Analytical Biochemistry</i> , 2014, 460, 9-15.	2.4	5
175	Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
176	Biochemical engineering IXâ€™ interdisciplinary foundations for creating new biotechnology: I. <i>Biotechnology and Bioengineering</i> , 1996, 52, 1-2.	3.3	4
177	Protein technologies. <i>Current Opinion in Biotechnology</i> , 2007, 18, 293-294.	6.6	3
178	Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia. <i>Blood</i> , 2014, 124, 3749-3749.	1.4	3
179	Coâ€™Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhancedâ€™Humoral Immunity. <i>Advanced Therapeutics</i> , 2022, 5, .	3.2	3
180	Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity Maturation. <i>Methods in Molecular Biology</i> , 2022, 2491, 29-62.	0.9	3

#	ARTICLE	IF	CITATIONS
181	Stochastic simulation of 2. μ . multicopy plasmid amplification in yeast. <i>Biotechnology Progress</i> , 1993, 9, 160-165.	2.6	2
182	Directed Evolution of Binding Proteins by Cell Surface Display: Analysis of the Screening Process. , 0, , 111-126.		1
183	Jay Bailey as mentor?The students' perspective. <i>Biotechnology and Bioengineering</i> , 2002, 79, 484-489.	3.3	1
184	Exploiting bias in a non-immune human antibody library to predict antigenicity. <i>Protein Engineering, Design and Selection</i> , 2011, 24, 845-853.	2.1	1
185	Engineered pore-forming proteins for the intracellular delivery of macromolecular therapeutics. , 2014, , .		1
186	Glutathione excretion in response to heterologous protein secretion in <i>saccharomyces cerevisiae</i> . <i>Biotechnology and Bioengineering</i> , 2000, 68, 389.	3.3	1
187	A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. <i>Blood</i> , 2015, 126, 118-118.	1.4	1
188	Directed evolution in chemical engineering. <i>AIChE Journal</i> , 2005, 51, 3083-3085.	3.6	0
189	Surface Marker Analysis in the Evaluation of Pleural Effusions: Unique Markers Can Assist in Distinguishing Malignant From Nonmalignant Effusions. <i>Chest</i> , 2010, 138, 340A.	0.8	0
190	Biochemical engineering IX-interdisciplinary foundations for creating new biotechnology: II. <i>Biotechnology and Bioengineering</i> , 2010, 52, 183-183.	3.3	0
191	CD8+ T-cell Responses Rapidly Select for Antigen-Negative Tumor Cells in the Prostate. <i>Cancer Immunology Research</i> , 2013, 1, 393-401.	3.4	0